Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.57 |
| ▸ | PRCP | P42785 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gacyclidine SCHEMBL7190367 | 1.00 | SIGMAR1 (0.57) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL4465879 | 1.00 | SIGMAR1 (0.57) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL3457748 | 1.00 | SIGMAR1 (0.57) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL5398234 | 0.99 | SIGMAR1 (0.56) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL1662223 | 0.99 | SIGMAR1 (0.56) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| SCHEMBL8206550 | 0.83 | MEN1 (0.42) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Hydrochloric Acid SCHEMBL8205944 | 0.82 | MEN1 (0.41) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| SCHEMBL7700857 | 0.81 | PRCP (0.51) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL5402379 | 0.79 | CYP1A2 (0.45) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL14053284 | 0.78 | GRIN1 (0.56) | SIGMAR1PRCPMEN1KMT2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1078 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589097-B2 | Apilimod compositions and methods of use | OrphAl Therapeutics Inc. (US) | 2026-03-31 | — | — | US | claimed |
| US-12539337-B2 | Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels | Molokanova, Elena (US) | 2026-02-03 | — | — | US | claimed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| WO-2025030033-A1 | APILIMOD COMPOSITIONS AND METHODS OF USE | ORPHAI THERAPEUTICS INC. (US) | 2025-02-06 | — | — | WO | claimed |
| US-20240350433-A1 | TREATMENT COMPOSITIONS AND METHODS | UNIV YALE (US) | 2024-10-24 | — | — | US | claimed |
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| US-11957688-B2 | Combination therapy with apilimod and glutamatergic agents | OrphAl Therapeutics Inc. (US) | 2024-04-16 | — | — | US | claimed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | claimed |
| US-20240066003-A1 | NEURODEVELOPMENTAL DISORDER THERAPY | ANAVEX LIFE SCIENCES CORP. (US) | 2024-02-29 | — | — | US | claimed |
| WO-2005094799-A2 | USE OF AN NMDA RECEPTOR ANTAGONIST FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY | AURIS MEDICAL AG (CH) | 2005-10-13 | — | — | WO | claimed |
| US-20050214338-A1 | Methods for the treatment of tinnitus induced by cochlear excitotoxicity | AURIS MEDICAL AG (CH) | 2005-09-29 | — | — | US | claimed |
| EP-1545551-A1 | DELIVERY OF MODULATORS OF GLUTAMATE-MEDIATED NEUROTRANSMISSION TO THE INNER EAR | Durect Corporation (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050032840-A1 | Novel therapeutic use of a thienylcyclohexylamine derivative | NEUREVA (FR) | 2005-02-10 | — | — | US | claimed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | claimed |
| WO-2004039371-A2 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF NEUROPATHIC PAIN | PHARMACIA CORPORATION (US) | 2004-05-13 | — | — | WO | claimed |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | claimed |
| WO-2004022069-A1 | DELIVERY OF MODULATORS OF GLUTAMATE-MEDIATED NEUROTRANSMISSION TO THE INNER EAR | DURECT CORPORATION (US) | 2004-03-18 | — | — | WO | claimed |
| EP-1359914-A2 | NOVEL THERAPEUTIC USE OF A THIENYLCYCLOHEXYLAMINE DERIVATIVE | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-11-12 | — | — | EP | claimed |
| WO-2002049647-A2 | NOVEL THERAPEUTIC USE OF A THIENYLCYCLOHEXYLAMINE DERIVATIVE | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-06-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589097-B2 | Apilimod compositions and methods of use | ZAP70, PIK3R4, PIKFYVE | SIGMAR1 2347/4885PRCP 4360/4885MEN1 4072/4885 |
| US-12539337-B2 | Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels | GRIN2B, GRIN2A, GRIN3A | SIGMAR1 123/4885PRCP 2604/4885MEN1 3762/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | SIGMAR1 3104/4885PRCP 1916/4885MEN1 1519/4885 |
| US-11957688-B2 | Combination therapy with apilimod and glutamatergic agents | GRIK4, GRIN3A, GRIN2A | SIGMAR1 958/4885PRCP 2505/4885MEN1 2781/4885 |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | GRIN2A, GRIN2B, GRIN3A | SIGMAR1 408/4885PRCP 4223/4885MEN1 4256/4885 |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | SIGMAR1 99/4885PRCP 1812/4885MEN1 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.